MXPA05012832A - Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4. - Google Patents

Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4.

Info

Publication number
MXPA05012832A
MXPA05012832A MXPA05012832A MXPA05012832A MXPA05012832A MX PA05012832 A MXPA05012832 A MX PA05012832A MX PA05012832 A MXPA05012832 A MX PA05012832A MX PA05012832 A MXPA05012832 A MX PA05012832A MX PA05012832 A MXPA05012832 A MX PA05012832A
Authority
MX
Mexico
Prior art keywords
ctla
disease
based immunotherapy
therapeutic endpoint
surrogate therapeutic
Prior art date
Application number
MXPA05012832A
Other languages
English (en)
Inventor
Geoffrey M Nichol
Original Assignee
Medarex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medarex Inc filed Critical Medarex Inc
Publication of MXPA05012832A publication Critical patent/MXPA05012832A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion provee un metodo de tratamiento utilizando anticuerpos de secuencia de humano en contra de CTLA-4 de humano; en particular, se proveen los metodos para tratamiento del cancer.
MXPA05012832A 2003-05-30 2004-05-28 Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4. MXPA05012832A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47506703P 2003-05-30 2003-05-30
PCT/US2004/016995 WO2005003298A2 (en) 2003-05-30 2004-05-28 Surrogate therapeutic endpoint for anti-ctla-4 based immunotherapy of disease

Publications (1)

Publication Number Publication Date
MXPA05012832A true MXPA05012832A (es) 2006-02-13

Family

ID=33563738

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05012832A MXPA05012832A (es) 2003-05-30 2004-05-28 Punto terminal terapeutico sustituto para inmunoterapia de enfermedad basada en anti-ctla-4.

Country Status (19)

Country Link
US (2) US7465446B2 (es)
EP (1) EP1639010B1 (es)
JP (1) JP2007502330A (es)
CN (1) CN1816567A (es)
AU (1) AU2004253865B2 (es)
CA (1) CA2527373A1 (es)
CY (1) CY1123535T1 (es)
DK (1) DK1639010T3 (es)
ES (1) ES2813928T3 (es)
HU (1) HUE051533T2 (es)
IL (1) IL172028A (es)
MX (1) MXPA05012832A (es)
NO (1) NO344368B1 (es)
NZ (1) NZ543768A (es)
PL (1) PL1639010T3 (es)
PT (1) PT1639010T (es)
SI (1) SI1639010T1 (es)
WO (1) WO2005003298A2 (es)
ZA (1) ZA200510125B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
AU2003234736B2 (en) * 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
DE10161767T1 (de) 2002-07-03 2018-06-07 Honjo Tasuku Immunopotenzierende Zusammensetzungen, die einen Anti-PD-L1 Antikörper enthalten
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
CA2566745A1 (en) 2004-05-20 2005-12-01 Zymogenetics, Inc. Methods of treating cancer using il-21 and monoclonal antibody therapy
US7473678B2 (en) * 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
GB0426644D0 (en) * 2004-12-03 2005-01-05 Univ Aberdeen T-cell modulation
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
DK1907424T3 (en) 2005-07-01 2015-11-09 Squibb & Sons Llc HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1)
EP1948214A4 (en) * 2005-11-08 2009-12-30 Medarex Inc ANTI-TNF-ALPHA TREATMENT FOR TREATING ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY TREATMENT
WO2007056539A2 (en) * 2005-11-08 2007-05-18 Medarex, Inc. Prophylaxis and treatment of enterocolitis associated with anti-ctla-4 antibody therapy
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
US9868961B2 (en) 2006-03-30 2018-01-16 The Regents Of The University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
US7919079B2 (en) * 2006-03-31 2011-04-05 Biosante Pharmaceuticals, Inc. Cancer immunotherapy compositions and methods of use
WO2008109075A2 (en) * 2007-03-05 2008-09-12 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to ctla-4 antagonists
WO2010014784A2 (en) * 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
DK2769737T3 (en) * 2009-07-20 2017-07-24 Bristol Myers Squibb Co COMBINATION OF ANTI-CTLA4 ANTIBODY WITH ETOPOSIDE FOR SYNERGISTIC TREATMENT OF PROLIFERATIVE DISEASES
BR112012008665A2 (pt) * 2009-10-12 2016-11-22 Pfizer tratamento de câncer
GB0920258D0 (en) * 2009-11-19 2010-01-06 Alligator Bioscience Ab New medical agents and use thereof
EP2960652B1 (en) 2010-04-16 2019-09-04 The Johns Hopkins University Compositions and methods for characterizing a myopathy
US9688740B2 (en) 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
SG11201609721WA (en) 2014-05-28 2016-12-29 Agenus Inc Anti-gitr antibodies and methods of use thereof
CN105296433B (zh) 2014-08-01 2018-02-09 中山康方生物医药有限公司 一种ctla4抗体、其药物组合物及其用途
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
KR20180063881A (ko) 2015-07-16 2018-06-12 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
IL299072A (en) 2015-12-02 2023-02-01 Memorial Sloan Kettering Cancer Center Antibodies and methods for using them
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
WO2018077385A1 (en) * 2016-10-25 2018-05-03 Biontech Rna Pharmaceuticals Gmbh Dose determination for immunotherapeutic agents
PT3551660T (pt) 2016-12-07 2023-11-30 Ludwig Inst For Cancer Res Ltd Anticorpos anti-ctla-4 e métodos de uso dos mesmos
SG11201907867TA (en) 2017-02-28 2019-09-27 Bristol Myers Squibb Co Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
JP7173993B2 (ja) 2017-05-19 2022-11-17 ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体
AU2019285344A1 (en) 2018-06-15 2020-12-10 Mina Therapeutics Limited Combination therapies comprising C/EBP alpha saRNA
EP3833762A4 (en) 2018-08-09 2022-09-28 Verseau Therapeutics, Inc. OLIGONUCLEOTIDE COMPOSITIONS FOR TARGETING CCR2 AND CSF1R AND THEIR USES
CA3139410A1 (en) * 2019-05-07 2020-11-12 Immunicom, Inc. Increasing responses to checkpoint inhibitors by extracorporeal apheresis
WO2022229644A1 (en) 2021-04-28 2022-11-03 Mina Therapeutics Limited Combination therapies comprising c/ebp alpha sarna

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP3214175A1 (en) * 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP2003520828A (ja) 2000-01-27 2003-07-08 ジェネティクス インスティテュート，エルエルシー Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AU2003234736B2 (en) 2002-04-12 2008-09-25 E. R. Squibb & Sons, L.L.C. Methods of treatment using CTLA-4 antibodies
US7465446B2 (en) 2003-05-30 2008-12-16 Medarex, Inc. Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
NZ568016A (en) 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens

Also Published As

Publication number Publication date
IL172028A (en) 2012-01-31
EP1639010A4 (en) 2006-08-09
PL1639010T3 (pl) 2020-11-30
AU2004253865B2 (en) 2011-06-23
US7465446B2 (en) 2008-12-16
EP1639010A2 (en) 2006-03-29
HUE051533T2 (hu) 2021-03-01
SI1639010T1 (sl) 2020-10-30
NZ543768A (en) 2009-07-31
DK1639010T3 (da) 2020-09-07
ZA200510125B (en) 2006-12-27
US7744875B2 (en) 2010-06-29
NO20056027L (no) 2006-02-20
PT1639010T (pt) 2020-09-04
EP1639010B1 (en) 2020-06-10
AU2004253865A1 (en) 2005-01-13
CN1816567A (zh) 2006-08-09
ES2813928T3 (es) 2021-03-25
WO2005003298A2 (en) 2005-01-13
JP2007502330A (ja) 2007-02-08
WO2005003298A3 (en) 2005-06-23
NO344368B1 (no) 2019-11-18
CY1123535T1 (el) 2022-03-24
CA2527373A1 (en) 2005-01-13
US20040241169A1 (en) 2004-12-02
US20090074752A1 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
CY1123535T1 (el) Υποκαταστατο θεραπευτικο τελικο σημειο για βασιζομενη σε anti-ctla-4 ανοσοθεραπεια ασθενειας
IL164287A (en) @Human antibodies @ against @@ - ctla @ for use @ in treatment @ cancer
MY176959A (en) Humanized antibodies that recognize beta amyloid peptide
IL244803B (en) Human anti-beta antibodies and their use
MY151032A (en) Treatment of tnf? related disorders
TNSN05300A1 (en) Treatment with anti-vegf antibodies
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
GEP20074222B (en) Antibodies to cd40
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
TW200636066A (en) Humanized antibodies that recognize beta amyloid peptide
MY150756A (en) Tumor theraphy with an anti-vegf antibody
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
TW200738270A (en) Method of treating depression using a TNFα antibody
MXPA04011550A (es) Tratamiento de carcinoma renal utilizando anticuerpos contra el receptor del factor de crecimiento epidermico.
UA89350C2 (uk) Гуманізоване антитіло, що зв'язує людський cd20
WO2007056540A3 (en) Tnf-alpha blocker treatment for enterocolitis associated with immunostimulatory therapeutic antibody therapy
IL187594A0 (en) Humanized anti-cd40 antibodies and their methods of use
TW200637574A (en) Treatment method
MX2009009636A (es) Metodos para tratar enfermedades oftalmicas.
SG148217A1 (en) Method for treating adamts-5-associated disease
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
SG146644A1 (en) Kid3 and kid3 antibodies that bind thereto
WO2004043239A3 (en) Antigen pipa and antibodies that bind thereto
WO2009049966A3 (en) Methods and tools for prognosis of cancer in her2+ patients
ATE490981T1 (de) Criptospezifische antikörper

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights